Compare Digital Realty Trust, Inc. (DLR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Merck & Co., Inc. — how do they compare? Digital Realty Trust, Inc. trades at $173.9 (market cap $64.05B), while Merck & Co., Inc. trades at $123.43 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 4.7× Digital Realty Trust, Inc.'s market cap, and Merck & Co., Inc. is trading nearer its 52-week high, Digital Realty Trust, Inc. nearer its low. Which is the better fit depends on your goals.
| DLR | MRK | |
|---|---|---|
Market Cap | $64.05B | $298.31B |
Sector | Real Estate | Health |
52-Week High | $203.91 | $129.52 |
52-Week Low | $147.93 | $77.60 |
Enterprise Value | $81.57B | $341.72B |
Dividend Yield | 2.82% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $177.92, down 1.38% on the day, with a bearish technical signal and mixed earnings history. The company shows strong fundamentals with 2025 revenue of $6.11B and net income of $1.31B, though its P/E ratio of 47.19 suggests premium valuation. Recent news highlights DLR's $7.8B acquisition of Blackstone's data center stake, positioning it for AI-driven growth.
DLR presents a growth opportunity in data center infrastructure supported by AI demand, with a consensus price target of $219.50 implying 23% upside. Risks include high debt levels, execution of recent acquisitions, and interest rate sensitivity. Analyst sentiment remains bullish with 59.57% buy ratings, but investors should weigh valuation concerns against long-term expansion potential.
Merck (MRK) trades at $123.485, down 0.44% on the day, with a bullish technical signal and strong institutional accumulation. The company reported solid earnings beats in recent quarters despite a Q1 2026 loss, maintains robust profitability with a 73.91% gross margin and 13.59% net margin, and is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Cash flow from operations remains healthy at $16.47B for 2025, supporting strategic investments and shareholder returns.
Outlook remains positive with a $137.30 consensus price target representing 11% upside, supported by 67.57% analyst buy ratings. Key opportunities include pipeline expansion via M&A and sustained profitability, while risks involve integration of acquisitions, patent pressures, and competitive threats in oncology. The stock's valuation at 34.02 P/E appears elevated but justified by growth prospects and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
